![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Chicago Reaffirms High Court Ruling Fortifies Opioid Marketing Suit
Chicago Reaffirms High Court Ruling Fortifies Opioid Marketing Suit
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GavelinfrontofBooks.gif?t=1434643836&width=430)
August 16, 2016
Chicago is firing back at drugmakers that dismissed the relevance of a high court ruling to the city’s False Claims Act suit against them over their promotion of opioids.
The city reaffirmed its stance in a court filing that a recent Supreme Court ruling — Universal Health Services v. Escobar — bolsters its case against the firms by holding companies accountable for complying with municipal regulations when receiving government payments.
Chicago filed suit against five companies that manufacture opioids — Purdue Pharma, Cephalon, Janssen, Endo Health Solutions and Actavis — contending in U.S. District Court for the Northern District of Illinois that they misrepresented the benefits of opioids. Separately, the city signed a four-year agreement with Pfizer for a code of conduct regarding its marketing of opioids.
This original suit was filed in June 2014.
Upcoming Events
-
21Oct